Samil Pharmaceutical Co.,Ltd

KOSE:A000520 Rapporto sulle azioni

Cap. di mercato: ₩343.8b

Samil PharmaceuticalLtd Crescita futura

Future criteri di controllo 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Samil PharmaceuticalLtd.

Informazioni chiave

n/a

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili38.2%
Tasso di crescita dei ricavin/a
Rendimento futuro del capitale proprion/a
Copertura analitica

Low

Ultimo aggiornamento05 Jun 2024

Aggiornamenti recenti sulla crescita futura

Nessun aggiornamento

Recent updates

Optimistic Investors Push Samil Pharmaceutical Co.,Ltd (KRX:000520) Shares Up 29% But Growth Is Lacking

Sep 13
Optimistic Investors Push Samil Pharmaceutical Co.,Ltd (KRX:000520) Shares Up 29% But Growth Is Lacking

We Think Samil PharmaceuticalLtd (KRX:000520) Is Taking Some Risk With Its Debt

Sep 11
We Think Samil PharmaceuticalLtd (KRX:000520) Is Taking Some Risk With Its Debt

Investor Optimism Abounds Samil Pharmaceutical Co.,Ltd (KRX:000520) But Growth Is Lacking

Jul 29
Investor Optimism Abounds Samil Pharmaceutical Co.,Ltd (KRX:000520) But Growth Is Lacking

Does Samil PharmaceuticalLtd (KRX:000520) Have A Healthy Balance Sheet?

May 24
Does Samil PharmaceuticalLtd (KRX:000520) Have A Healthy Balance Sheet?

There's Reason For Concern Over Samil Pharmaceutical Co.,Ltd's (KRX:000520) Massive 29% Price Jump

Mar 30
There's Reason For Concern Over Samil Pharmaceutical Co.,Ltd's (KRX:000520) Massive 29% Price Jump

Samil PharmaceuticalLtd's (KRX:000520) Earnings Are Of Questionable Quality

Mar 21
Samil PharmaceuticalLtd's (KRX:000520) Earnings Are Of Questionable Quality

Here's Why Samil PharmaceuticalLtd (KRX:000520) Has A Meaningful Debt Burden

Apr 01
Here's Why Samil PharmaceuticalLtd (KRX:000520) Has A Meaningful Debt Burden

Samil PharmaceuticalLtd (KRX:000520) Has Gifted Shareholders With A Fantastic 141% Total Return On Their Investment

Mar 11
Samil PharmaceuticalLtd (KRX:000520) Has Gifted Shareholders With A Fantastic 141% Total Return On Their Investment

Are Dividend Investors Getting More Than They Bargained For With Samil Pharmaceutical Co.,Ltd's (KRX:000520) Dividend?

Feb 15
Are Dividend Investors Getting More Than They Bargained For With Samil Pharmaceutical Co.,Ltd's (KRX:000520) Dividend?

Should You Be Concerned About Samil Pharmaceutical Co.,Ltd's (KRX:000520) ROE?

Jan 20
Should You Be Concerned About Samil Pharmaceutical Co.,Ltd's (KRX:000520) ROE?

Why It Might Not Make Sense To Buy Samil Pharmaceutical Co.,Ltd (KRX:000520) For Its Upcoming Dividend

Dec 24
Why It Might Not Make Sense To Buy Samil Pharmaceutical Co.,Ltd (KRX:000520) For Its Upcoming Dividend

Samil PharmaceuticalLtd (KRX:000520) Has Gifted Shareholders With A Fantastic 221% Total Return On Their Investment

Dec 09
Samil PharmaceuticalLtd (KRX:000520) Has Gifted Shareholders With A Fantastic 221% Total Return On Their Investment

What Is The Ownership Structure Like For Samil Pharmaceutical Co.,Ltd (KRX:000520)?

Nov 18
What Is The Ownership Structure Like For Samil Pharmaceutical Co.,Ltd (KRX:000520)?

In questa sezione di solito presentiamo le proiezioni di crescita dei ricavi e degli utili basate sulle stime di consenso degli analisti professionisti per aiutare gli investitori a capire la capacità della società di generare profitti. Tuttavia, poiché Samil PharmaceuticalLtd non ha fornito dati sufficienti sul passato e non ha previsioni degli analisti, i suoi utili futuri non possono essere calcolati in modo affidabile estrapolando i dati passati o utilizzando le previsioni degli analisti.

Si tratta di una situazione piuttosto rara, dato che il 97% delle società coperte da SimplyWall St dispone di dati finanziari passati.

Previsioni di crescita degli utili e dei ricavi

KOSE:A000520 - Stime future degli analisti e dati finanziari passati (KRW Millions )
DataRicaviGuadagniFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/2024248,200N/AN/AN/A1
6/30/2024210,733-1,155-7,88215,330N/A
3/31/2024204,905-786-14,9718,629N/A
12/31/2023196,3461,664-12,59011,746N/A
9/30/2023189,2932,600-18,707-43,369N/A
6/30/2023183,0601,336-28,155-12,562N/A
3/31/2023179,566343-33,5603,887N/A
12/31/2022179,676-28-44,5024,154N/A
9/30/2022170,510-4,989-53,80241,099N/A
6/30/2022158,910-4,740-40,59315,161N/A
3/31/2022147,877-5,619-34,9331,437N/A
12/31/2021134,247-5,347-31,1941,417N/A
9/30/2021129,974-2,761-24,913-1,229N/A
6/30/2021127,287-1,327-20,164119N/A
3/31/2021122,793132-20,0384,736N/A
12/31/2020122,9991,341-9,4367,775N/A
9/30/2020123,1149402,74715,430N/A
6/30/2020122,308729-9,55711,450N/A
3/31/2020123,1021,4292,48616,455N/A
12/31/2019121,107786-3,72910,590N/A
9/30/2019114,364-1,251-13,26740N/A
6/30/2019107,856-3,368-54,677N/A
3/31/2019102,805-6,461-7,234-2,305N/A
12/31/201894,600-8,563-6,538-2,622N/A
9/30/201896,882-5,165-2,8991,319N/A
6/30/201894,916-4,605-3,0352,217N/A
3/31/201892,286-2,797N/A3,258N/A
12/31/201792,038-1,267N/A3,791N/A
9/30/201790,658-1,434N/A-680N/A
6/30/201792,118898N/A1,539N/A
3/31/201794,685948N/A5,206N/A
12/31/201696,758887N/A5,634N/A
9/30/201694,010306N/A9,953N/A
6/30/201692,625140N/A5,840N/A
3/31/201688,656553N/A1,357N/A
12/31/201588,136588N/A2,920N/A
9/30/201585,795-2,986N/A-1,492N/A
6/30/201585,439-6,170N/A-4,921N/A
3/31/201585,849-10,179N/A-11,314N/A
12/31/201485,461-11,190N/A-11,923N/A
9/30/201487,6831,148N/A-12,731N/A
6/30/201487,5453,601N/A-6,621N/A
3/31/201489,2077,191N/A-586N/A
12/31/201389,2297,930N/A-3,990N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Insufficient data to determine if A000520's forecast earnings growth is above the savings rate (2.6%).

Guadagni vs Mercato: Insufficient data to determine if A000520's earnings are forecast to grow faster than the KR market

Guadagni ad alta crescita: Insufficient data to determine if A000520's earnings are expected to grow significantly over the next 3 years.

Ricavi vs Mercato: Insufficient data to determine if A000520's revenue is forecast to grow faster than the KR market.

Ricavi ad alta crescita: Insufficient data to determine if A000520's revenue is forecast to grow faster than 20% per year.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Insufficient data to determine if A000520's Return on Equity is forecast to be high in 3 years time

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y